<DOC>
	<DOCNO>NCT00347399</DOCNO>
	<brief_summary>The purpose study determine combination therapy intravitreal bevacizumab 4 day application photodynamic therapy could improve visual outcome patient neovascular age relate macular degeneration .</brief_summary>
	<brief_title>Bevacizumab Photodynamic Therapy Neovascular Age Related Macular Degeneration</brief_title>
	<detailed_description>The neovascular age relate macular degeneration ( AMD ) important cause legal blindness adult older 50 year . Currently treatment photodynamic therapy offer stabilization limit visual improvement 2 year therapy . Bevacizumab report effective use intravenous injection AMD . But serious side effect report use drug oncologic patient . The intravitreal use report limited case report safety efficacy determine . The purpose study efficacy safety 2.5 mg intravitreal bevacizumab AMD 4 day photodynamic therapy verteporfin</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Verteporfin</mesh_term>
	<criteria>55 year old neovascular Age relate acular degeneration subfoveolar neovascular membrane best correct visual acuity well 20/200 snellen ( 1.0 logMAR ) Previously treat eye glaucoma diabetes mellitus uncontrolled hypertension coronary artery disease</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2006</verification_date>
	<keyword>macular degeneration</keyword>
	<keyword>antibody</keyword>
	<keyword>angiogenesis inhibitor</keyword>
</DOC>